Changfeng Pharmaceutical Rushes to List on Hong Kong Stock Exchange, Its Self-developed Product GW006 Approved by FDA

On November 28, Changfeng Pharmaceutical Co., Ltd. filed an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities and China Merchants International as joint sponsors.

It is known that Changfeng Pharmaceutical focuses on inhalation formulations and positions its product portfolio in respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Its first approved product CF017 (inhaled budesonide suspension for the treatment of bronchial asthma) was approved in May 2021 and quickly included in the China centralized procurement (VBP) plan.

Changfeng Pharmaceutical's innovative drug development is accelerating continuously, exploring innovative inhalation formulations such as liposome and siRNA, and expanding its therapeutic areas to new disease areas including central nervous system (CNS) diseases and anti-infective. The Company is also developing new treatment methods such as bronchial valve (EBV) and potential first-in-class or first-in-China treatments for diseases that severely affect patients' lives, such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

In addition, Changfeng Pharmaceutical is accelerating its internationalization layout and is developing more than 20 candidate products globally in major markets such as China, the United States, and Europe, as well as emerging markets such as Southeast Asia and South America, and expects to have at least five products approved within the next four years. Currently, Changfeng Pharmaceutical has received one FDA NDA approval, namely GW006 (aformaldehyde solution for the treatment of chronic obstructive pulmonary disease (COPD)).